{"id":"verteporfin-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Photosensitivity reaction"},{"rate":null,"effect":"Vision decrease or blurred vision"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Back pain"}]},"_chembl":{"chemblId":"CHEMBL5314346","moleculeType":"Small molecule"},"_dailymed":{"setId":"952f4c80-50b1-4308-9ee6-311ffefb13df","title":"VISUDYNE (VERTEPORFIN FOR INJECTION) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [BAUSCH HEALTH US LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Verteporfin is a lipophilic porphyrin derivative that preferentially localizes to neovascular endothelial cells and abnormal vasculature. Upon intravenous administration followed by exposure to non-thermal red light (689 nm wavelength), verteporfin undergoes photochemical activation to produce singlet oxygen and reactive oxygen species, leading to selective destruction of the targeted abnormal blood vessels through thrombosis and vessel occlusion.","oneSentence":"Verteporfin is a photosensitizing agent that accumulates in abnormal blood vessels and, when activated by light, generates reactive oxygen species to destroy those vessels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:12.463Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (AMD) with predominantly classic choroidal neovascularization"},{"name":"Pathologic myopia with choroidal neovascularization"},{"name":"Polypoidal choroidal vasculopathy"}]},"trialDetails":[{"nctId":"NCT07488988","phase":"PHASE2","title":"SCARFREE-001: Verteporfin for Scar Prevention","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","startDate":"2026-06","conditions":"Surgical Scar","enrollment":12},{"nctId":"NCT06807359","phase":"PHASE1, PHASE2","title":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","status":"RECRUITING","sponsor":"SpectraCure AB","startDate":"2025-01-06","conditions":"Prostate Cancer","enrollment":43},{"nctId":"NCT00527475","phase":"PHASE2","title":"Ranibizumab and Reduced Fluence PDT for AMD","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2007-05","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT03941587","phase":"NA","title":"Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment","status":"COMPLETED","sponsor":"Singapore National Eye Centre","startDate":"2021-02-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT03067051","phase":"PHASE1, PHASE2","title":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","status":"RECRUITING","sponsor":"SpectraCure AB","startDate":"2017-03-21","conditions":"Recurrent Prostate Cancer","enrollment":66},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT02120950","phase":"PHASE4","title":"Aflibercept in Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-05-29","conditions":"Neovascular Macular Degeneration","enrollment":333},{"nctId":"NCT04075188","phase":"NA","title":"Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","startDate":"2017-09-18","conditions":"Choroidal Neovascularization, Choroid Disease","enrollment":17},{"nctId":"NCT01922102","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-11","conditions":"Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)","enrollment":457},{"nctId":"NCT02457026","phase":"NA","title":"Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2016-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT01482910","phase":"PHASE3","title":"VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12","conditions":"Macular Degeneration","enrollment":304},{"nctId":"NCT01032109","phase":"NA","title":"Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2006-10","conditions":"Age-related Macular Degeneration","enrollment":45},{"nctId":"NCT01666236","phase":"PHASE4","title":"Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy","status":"WITHDRAWN","sponsor":"Federal University of São Paulo","startDate":"2012-09","conditions":"Choroidal Neovascularization, Retinal Pigment Epithelial Detachment","enrollment":""},{"nctId":"NCT01217944","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10","conditions":"Pathological Myopia","enrollment":277},{"nctId":"NCT01256580","phase":"NA","title":"Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD","status":"WITHDRAWN","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2010-08","conditions":"Choroidal Neovascularization, Myopia, Punctate Inner Choroidopathy (PIC)","enrollment":""},{"nctId":"NCT01968486","phase":"PHASE1","title":"Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2012-06","conditions":"Myopia, Degenerative","enrollment":60},{"nctId":"NCT01325181","phase":"PHASE1, PHASE2","title":"Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"Jang Won Heo","startDate":"2009-07","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":34},{"nctId":"NCT00211419","phase":"PHASE1","title":"Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"","conditions":"Maculopathy, Age-Related","enrollment":""},{"nctId":"NCT00726973","phase":"NA","title":"Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)","status":"WITHDRAWN","sponsor":"Lahey Clinic","startDate":"2006-12","conditions":"Macular Edema","enrollment":""},{"nctId":"NCT00492284","phase":"PHASE2","title":"Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)","status":"COMPLETED","sponsor":"QLT Inc.","startDate":"2007-07","conditions":"Choroidal Neovascularization, Macular Degeneration","enrollment":162},{"nctId":"NCT00433017","phase":"PHASE2, PHASE3","title":"Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-05","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":255},{"nctId":"NCT00436553","phase":"PHASE3","title":"Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":321},{"nctId":"NCT00049959","phase":"PHASE3","title":"Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.","status":"TERMINATED","sponsor":"QLT Inc.","startDate":"","conditions":"Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome","enrollment":""},{"nctId":"NCT00546936","phase":"PHASE2","title":"Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis","status":"UNKNOWN","sponsor":"Barnes Retina Institute","startDate":"2007-10","conditions":"Presumed Ocular Histoplasmosis (POHS)","enrollment":30},{"nctId":"NCT00813891","phase":"PHASE4","title":"Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"Macular Degeneration, Visual Acuity","enrollment":180},{"nctId":"NCT00134667","phase":"PHASE4","title":"Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2005-03","conditions":"Age-Related Macular Degeneration","enrollment":360},{"nctId":"NCT00135837","phase":"PHASE4","title":"Photodynamic Therapy in Occult-Only Lesions (POOL)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-06","conditions":"Age-Related Macular Degeneration","enrollment":202},{"nctId":"NCT00121407","phase":"PHASE3","title":"Visudyne® in Occult (VIO)","status":"COMPLETED","sponsor":"QLT Inc.","startDate":"2002-03","conditions":"Macular Degeneration","enrollment":364}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Verteporfin for injection","genericName":"Verteporfin for injection","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Verteporfin is a photosensitizing agent that accumulates in abnormal blood vessels and, when activated by light, generates reactive oxygen species to destroy those vessels. Used for Age-related macular degeneration (AMD) with predominantly classic choroidal neovascularization, Pathologic myopia with choroidal neovascularization, Polypoidal choroidal vasculopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}